The abstract is read at the publisher; the summary is JClub's.
Holding biologic or targeted synthetic DMARD therapy for 2 weeks around a supplemental COVID-19 mRNA dose did not significantly change SARS-CoV-2 spike IgG GMFR (hold/continue GMFR ratio 0.96).
- Why it matters: Patients with inflammatory arthritis may respond differently to supplemental vaccination depending on immunomodulatory drugs, and clinicians need evidence on whether temporary medication interruption improves antibody responses without worsening disease.
- What they did: In the COVER randomized clinical pragmatic trial (Nov 2021–May 2024) of 840 participants with rheumatoid arthritis, psoriatic arthritis, or axial spondylarthritis, patients were randomized to continue or hold anti-TNF, anti-IL-17, abatacept, or a JAK inhibitor for 2 weeks after the supplemental dose, with IgG GMFR measured from baseline to 6 weeks.
- The result: Humoral immunogenicity increased in all arms, with no significant between-group difference (GMFR ratio 0.96; 95% CI, 0.36-2.56), but holding therapy increased flare risk (odds ratio 2.27) and was most pronounced with JAKi, with comparable adverse events.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.